Current Protein Identity：Q9UGN5
New Search
Difference tags compare only the current result set; every original PDB and assembly record remains separate.
Related-Structure Differences
Each row represents one biological assembly in one PDB entry; multiple monomers of the same protein are listed separately.
| PDB Entry | Assembly / Oligomeric State | Construct | Mutations and Modifications | Ligands, Ions and Non-polymers | Experimental Method | Experimental Conditions | Structure Quality |
|---|---|---|---|---|---|---|---|
| 3KCZ Human poly(ADP-ribose) polymerase 2, catalytic fragment in complex with an inhibitor 3-aminobenzamide Deposited 2009-10-22 | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric（1） Consistent with protein count |
Chain A
235–579（345 aa）
Fragment：Catalytic domain
|
Not recorded | 3AB 3-aminobenzamide × 1 GOL GLYCEROL × 1 | X-RAY DIFFRACTION |
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 9；277 K；22% PEG 3350, 0.1M Tris-HCl, 0.01M 3-aminobenzamide, pH 9.0, VAPOR DIFFUSION, SITTING DROP, temperature 277K
|
Resolution 2.00 Å R-free 0.237 |
| 3KCZ Human poly(ADP-ribose) polymerase 2, catalytic fragment in complex with an inhibitor 3-aminobenzamide Deposited 2009-10-22 | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric（1） Consistent with protein count |
Chain B
235–579（345 aa）
Fragment：Catalytic domain
|
Not recorded | 3AB 3-aminobenzamide × 1 GOL GLYCEROL × 1 | X-RAY DIFFRACTION |
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 9；277 K；22% PEG 3350, 0.1M Tris-HCl, 0.01M 3-aminobenzamide, pH 9.0, VAPOR DIFFUSION, SITTING DROP, temperature 277K
|
Resolution 2.00 Å R-free 0.237 |
| 3KJD Human poly(ADP-ribose) polymerase 2, catalytic fragment in complex with an inhibitor ABT-888 Deposited 2009-11-03 | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric（1） Consistent with protein count |
Chain A
235–579（345 aa）
Fragment：catalytic domain
|
Not recorded | 78P (2R)-2-(7-carbamoyl-1H-benzimidazol-2-yl)-2-methylpyrrolidinium × 1 GOL GLYCEROL × 1 | X-RAY DIFFRACTION |
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；277 K；25% PEG 3350, 0.1M Tris, 0.25M NaCl, pH 8.5, VAPOR DIFFUSION, SITTING DROP, temperature 277K
|
Resolution 1.95 Å R-free 0.232 |
| 3KJD Human poly(ADP-ribose) polymerase 2, catalytic fragment in complex with an inhibitor ABT-888 Deposited 2009-11-03 | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric（1） Consistent with protein count |
Chain B
235–579（345 aa）
Fragment：catalytic domain
|
Not recorded | 78P (2R)-2-(7-carbamoyl-1H-benzimidazol-2-yl)-2-methylpyrrolidinium × 1 GOL GLYCEROL × 1 | X-RAY DIFFRACTION |
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；277 K；25% PEG 3350, 0.1M Tris, 0.25M NaCl, pH 8.5, VAPOR DIFFUSION, SITTING DROP, temperature 277K
|
Resolution 1.95 Å R-free 0.232 |
| 4PJV Structure of PARP2 catalytic domain bound to inhibitor BMN 673 Deposited 2014-05-12 | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric（1） Consistent with protein count |
Chain A
235–579（345 aa）
Fragment：PARP2 HELICAL AND CATALYTIC DOMAINS (UNP residues 235-579)
|
Not recorded | 2YQ (8S,9R)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-2,7,8,9-tetrahydro-3H-pyrido[4,3,2-de]phthalazin-3-one × 1 GOL GLYCEROL × 2 | X-RAY DIFFRACTION |
X-ray crystallization conditions
VAPOR DIFFUSION；pH 7.5；289 K；(W/V) POLYETHYLENE GLYCOL 3350, 333 mM SODIUM CHLORIDE.
|
Resolution 2.50 Å R-free 0.287 |
| 4PJV Structure of PARP2 catalytic domain bound to inhibitor BMN 673 Deposited 2014-05-12 | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric（1） Consistent with protein count |
Chain B
235–579（345 aa）
Fragment：PARP2 HELICAL AND CATALYTIC DOMAINS (UNP residues 235-579)
|
Not recorded | 2YQ (8S,9R)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-2,7,8,9-tetrahydro-3H-pyrido[4,3,2-de]phthalazin-3-one × 1 GOL GLYCEROL × 1 | X-RAY DIFFRACTION |
X-ray crystallization conditions
VAPOR DIFFUSION；pH 7.5；289 K；(W/V) POLYETHYLENE GLYCOL 3350, 333 mM SODIUM CHLORIDE.
|
Resolution 2.50 Å R-free 0.287 |
| 4TVJ HUMAN ARTD2 (PARP2) - CATALYTIC DOMAIN IN COMPLEX WITH OLAPARIB Deposited 2014-06-27 | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: Monomeric（1） Consistent with protein count |
Chain A
235–579（345 aa）
|
Not recorded | 09L 4-(3-{[4-(cyclopropylcarbonyl)piperazin-1-yl]carbonyl}-4-fluorobenzyl)phthalazin-1(2H)-one × 1 GOL GLYCEROL × 2 | X-RAY DIFFRACTION |
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；277 K；25% PEG3350, 0.1M Tris
|
Resolution 2.10 Å R-free 0.231 |
| 4TVJ HUMAN ARTD2 (PARP2) - CATALYTIC DOMAIN IN COMPLEX WITH OLAPARIB Deposited 2014-06-27 | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: Monomeric（1） Consistent with protein count |
Chain B
235–579（345 aa）
|
Not recorded | 09L 4-(3-{[4-(cyclopropylcarbonyl)piperazin-1-yl]carbonyl}-4-fluorobenzyl)phthalazin-1(2H)-one × 1 GOL GLYCEROL × 1 | X-RAY DIFFRACTION |
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；277 K；25% PEG3350, 0.1M Tris
|
Resolution 2.10 Å R-free 0.231 |
| 4ZZX Structure of PARP2 catalytic domain bound to an isoindolinone inhibitor Deposited 2015-04-15 | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric（1） Consistent with protein count |
Chain A
223–583（361 aa）
Fragment：CATALYTIC DOMAIN, UNP RESIDUES 223-583
|
Not recorded | FSU 2-(3-methoxypropyl)-3-oxo-2,3-dihydro-1H-isoindole-4-carboxamide × 1 | X-RAY DIFFRACTION |
X-ray crystallization conditions
277 K；25% PEG4000, 0.2M MAGNESIUM CHLORIDE, 0.1 M TRIS PH 8.5, 277K
|
Resolution 1.65 Å R-free 0.244 |
| 4ZZX Structure of PARP2 catalytic domain bound to an isoindolinone inhibitor Deposited 2015-04-15 | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric（1） Consistent with protein count |
Chain B
223–583（361 aa）
Fragment：CATALYTIC DOMAIN, UNP RESIDUES 223-583
|
Not recorded | FSU 2-(3-methoxypropyl)-3-oxo-2,3-dihydro-1H-isoindole-4-carboxamide × 1 | X-RAY DIFFRACTION |
X-ray crystallization conditions
277 K；25% PEG4000, 0.2M MAGNESIUM CHLORIDE, 0.1 M TRIS PH 8.5, 277K
|
Resolution 1.65 Å R-free 0.244 |
| 4ZZY Structure of human PARP2 catalytic domain bound to an isoindolinone inhibitor Deposited 2015-04-15 | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric（1） Consistent with protein count |
Chain A
223–583（361 aa）
Fragment：CATALYTIC DOMAIN, UNP RESIDUES 223-583
|
Not recorded | D7N 2-[1-(4,4-Difluorocyclohexyl)-piperidin-4-yl]-6-fluoro-3-oxo-2,3-dihydro-1H-isoindole-4-carboxamide × 1 | X-RAY DIFFRACTION |
X-ray crystallization conditions
25% PEG4000, 0.2M MAGNESIUM CLORIDE, 0.1 M TRIS PH 8.5
|
Resolution 2.20 Å R-free 0.280 |
| 5D5K Crystal Structure NLS from human PARP-2 complexed with Importin alpha delta IBB Deposited 2015-08-10 | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric（2） Consistent with protein count |
Chain B
1–78（78 aa）
Fragment：unp residues 1-78
|
Not recorded | No recorded non-water small molecule | X-RAY DIFFRACTION |
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5.6；295 K；0.6-0.7M sodium citrate, 0.1M sodium citrate buffer pH 5.6, and 7-10mM DTT
|
Resolution 1.90 Å R-free 0.171 |
| 5DSY Crystal structure of constitutively active PARP-2 Deposited 2015-09-17 | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric（1） Consistent with protein count |
Chain A
348–583（236 aa）
Fragment：unp residues 348-583
|
Not recorded | UHB 2-[4-[(2S,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-bis(oxidanyl)oxolan-2-yl]carbonylpiperazin-1-yl]-N-(1-oxidanylidene-2,3-dihydroisoindol-4-yl)ethanamide × 1 | X-RAY DIFFRACTION |
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8；298 K；2.55-2.65 M NaCl and 0.1 M Tris
|
Resolution 2.70 Å R-free 0.248 |
| 5DSY Crystal structure of constitutively active PARP-2 Deposited 2015-09-17 | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric（1） Consistent with protein count |
Chain B
348–583（236 aa）
Fragment：unp residues 348-583
|
Not recorded | UHB 2-[4-[(2S,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-bis(oxidanyl)oxolan-2-yl]carbonylpiperazin-1-yl]-N-(1-oxidanylidene-2,3-dihydroisoindol-4-yl)ethanamide × 1 | X-RAY DIFFRACTION |
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8；298 K；2.55-2.65 M NaCl and 0.1 M Tris
|
Resolution 2.70 Å R-free 0.248 |
| 5DSY Crystal structure of constitutively active PARP-2 Deposited 2015-09-17 | Assembly 3 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric（1） Consistent with protein count |
Chain C
348–583（236 aa）
Fragment：unp residues 348-583
|
Not recorded | UHB 2-[4-[(2S,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-bis(oxidanyl)oxolan-2-yl]carbonylpiperazin-1-yl]-N-(1-oxidanylidene-2,3-dihydroisoindol-4-yl)ethanamide × 1 | X-RAY DIFFRACTION |
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8；298 K；2.55-2.65 M NaCl and 0.1 M Tris
|
Resolution 2.70 Å R-free 0.248 |
| 5DSY Crystal structure of constitutively active PARP-2 Deposited 2015-09-17 | Assembly 4 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric（1） Consistent with protein count |
Chain D
348–583（236 aa）
Fragment：unp residues 348-583
|
Not recorded | UHB 2-[4-[(2S,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-bis(oxidanyl)oxolan-2-yl]carbonylpiperazin-1-yl]-N-(1-oxidanylidene-2,3-dihydroisoindol-4-yl)ethanamide × 1 | X-RAY DIFFRACTION |
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8；298 K；2.55-2.65 M NaCl and 0.1 M Tris
|
Resolution 2.70 Å R-free 0.248 |
| 6F1K Structure of ARTD2/PARP2 WGR domain bound to double strand DNA without 5'phosphate Deposited 2017-11-22 | Assembly 1 Protein–DNA Monomer；Protein × 1 PDB declaration: trimeric（3） Consistent with all polymers |
Chain A
90–218（129 aa）
|
Not recorded | GOL GLYCEROL × 1 CL CHLORIDE ION × 2 | X-RAY DIFFRACTION |
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4.9；277 K；PEG MME 5000
0.1 M Na-acetate
ethylene glyco
|
Resolution 2.20 Å R-free 0.250 |
| 6F5B Structure of ARTD2/PARP2 WGR domain bound to double stranded DNA with 5'phosphate Deposited 2017-12-01 | Assembly 1 Protein–DNA Homooligomer；Protein × 2 PDB declaration: hexameric（6） Consistent with all polymers |
Chain A
90–218（129 aa）
Chain B
90–218（129 aa）
|
Not recorded | No recorded non-water small molecule | X-RAY DIFFRACTION |
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4.5；277 K；12 % v/v Polypropylene glycol 400
0.1 M Na-acetate
3 % 2 propanol
|
Resolution 2.80 Å R-free 0.274 |
| 6F5F Structure of ARTD2/PARP2 WGR domain bound to double strand DNA with 5 nucleotide overhang and 5'phosphate Deposited 2017-12-01 | Assembly 1 Protein–DNA Homooligomer；Protein × 2 PDB declaration: tetrameric（4） Consistent with all polymers |
Chain A
90–218（129 aa）
Chain C
90–218（129 aa）
|
Not recorded | No recorded non-water small molecule | X-RAY DIFFRACTION |
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；277 K；0.2 M Na-formate
20 % PEG 3350
20 % glycerol
|
Resolution 2.98 Å R-free 0.275 |
| 6F5F Structure of ARTD2/PARP2 WGR domain bound to double strand DNA with 5 nucleotide overhang and 5'phosphate Deposited 2017-12-01 | Assembly 2 Protein–DNA Homooligomer；Protein × 2 PDB declaration: tetrameric（4） Consistent with all polymers |
Chain B
90–218（129 aa）
Chain D
90–218（129 aa）
|
Not recorded | No recorded non-water small molecule | X-RAY DIFFRACTION |
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；277 K；0.2 M Na-formate
20 % PEG 3350
20 % glycerol
|
Resolution 2.98 Å R-free 0.275 |
| 6TX3 HPF1 bound to catalytic fragment of PARP2 Deposited 2020-01-13 | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric（2） Consistent with protein count |
Chain B
230–253（24 aa）
Chain B
348–583（236 aa）
|
Not recorded | UHB 2-[4-[(2S,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-bis(oxidanyl)oxolan-2-yl]carbonylpiperazin-1-yl]-N-(1-oxidanylidene-2,3-dihydroisoindol-4-yl)ethanamide × 1 | X-RAY DIFFRACTION |
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6；293 K；0.1 M MES pH 6, 25% v/v pentaerythritol propoxylate (5/4 PO/OH)
|
Resolution 2.96 Å R-free 0.260 |
| 6USJ Structure of two nucleosomes bridged by human PARP2 Deposited 2019-10-27 | Assembly 1 Protein–DNA Heteromer；Protein × 18 PDB declaration: 22-meric（22） Consistent with all polymers |
Chain U
1–570（570 aa）
Chain V
1–570（570 aa）
|
Mutation：Q112R, F113D Mutation：Q112R, F113D | No recorded non-water small molecule | ELECTRON MICROSCOPY |
cryo-EM buffer
pH 7.5；Buffer was pH-adjusted and filtered through a 0.22 um filter.
cryo-EM vitrification conditions
Cryogen ETHANE；Blot time 2s, blot force 0
|
Resolution 10.50 Å |
| 6X0L Bridging of double-strand DNA break activates PARP2/HPF1 to modify chromatin Deposited 2020-05-16 | Assembly 1 Protein–DNA Heteromer；Protein × 3 PDB declaration: heptameric（7） Consistent with all polymers |
Chain P
1–570（570 aa）
Chain R
1–570（570 aa）
|
Not recorded | No recorded non-water small molecule | ELECTRON MICROSCOPY |
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.90 Å |
| 6X0M Bridging of double-strand DNA break activates PARP2/HPF1 to modify chromatin Deposited 2020-05-16 | Assembly 1 Protein–DNA Heteromer；Protein × 4 PDB declaration: octameric（8） Consistent with all polymers |
Chain P
1–570（570 aa）
Chain p
1–570（570 aa）
|
Not recorded | No recorded non-water small molecule | ELECTRON MICROSCOPY |
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 6.30 Å |
| 6X0N Bridging of double-strand DNA break activates PARP2/HPF1 to modify chromatin Deposited 2020-05-16 | Assembly 1 Protein–DNA Heteromer；Protein × 19 PDB declaration: 23-meric（23） Consistent with all polymers |
Chain P
1–570（570 aa）
Chain R
1–570（570 aa）
|
Not recorded | No recorded non-water small molecule | ELECTRON MICROSCOPY |
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 10.00 Å |
| 7AEO Human ARTD2 in complex with DNA oligonucleotides Deposited 2020-09-17 | Assembly 1 Protein–DNA Homooligomer；Protein × 2 PDB declaration: hexameric（6） Consistent with all polymers |
Chain A
90–583（494 aa）
|
Not recorded | SO4 SULFATE ION × 4 | X-RAY DIFFRACTION |
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；277 K；Sample was crystallized in 0.1 M MES pH 6.5 and 1 M ammonium sulfate.
Cryo solution was a mixture of 10% (v/v) glycerol, 10% (v/v) diethylene glycol, and 10% (v/v) 2-propanol with the crystallization conditions
|
Resolution 2.80 Å R-free 0.271 |
| 7R59 PARP2 catalytic domain in complex with OUL245 Deposited 2022-02-10 | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric（1） Consistent with protein count |
Chain A
235–583（349 aa）
|
Not recorded | GOL GLYCEROL × 1 I5F [1,2,4]triazolo[3,4-b][1,3]benzothiazol-6-ol × 1 | X-RAY DIFFRACTION |
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；277 K；100 mM Tris pH 9.5 and 20% PEG 3350
|
Resolution 2.00 Å R-free 0.238 |
| 8HE8 Human ADP-ribosyltransferase 2 (PARP2) catalytic domain bound to a quinazoline-2,4(1H,3H)-dione inhibitor Deposited 2022-11-07 | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric（1） Consistent with protein count |
Chain A
231–581（351 aa）
|
Not recorded | GOL GLYCEROL × 1 1WI 1-[[4-fluoranyl-3-(3-oxidanylidene-4-pentan-3-yl-piperazin-1-yl)carbonyl-phenyl]methyl]quinazoline-2,4-dione × 1 | X-RAY DIFFRACTION |
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；291 K；25% PEG-3350, 0.1 M Tris-HCl pH 8.3-8.5
|
Resolution 3.05 Å R-free 0.256 |
| 8HE8 Human ADP-ribosyltransferase 2 (PARP2) catalytic domain bound to a quinazoline-2,4(1H,3H)-dione inhibitor Deposited 2022-11-07 | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric（1） Consistent with protein count |
Chain B
231–581（351 aa）
|
Not recorded | GOL GLYCEROL × 1 1WI 1-[[4-fluoranyl-3-(3-oxidanylidene-4-pentan-3-yl-piperazin-1-yl)carbonyl-phenyl]methyl]quinazoline-2,4-dione × 1 | X-RAY DIFFRACTION |
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；291 K；25% PEG-3350, 0.1 M Tris-HCl pH 8.3-8.5
|
Resolution 3.05 Å R-free 0.256 |
| 8HE8 Human ADP-ribosyltransferase 2 (PARP2) catalytic domain bound to a quinazoline-2,4(1H,3H)-dione inhibitor Deposited 2022-11-07 | Assembly 3 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric（1） Consistent with protein count |
Chain C
231–581（351 aa）
|
Not recorded | 1WI 1-[[4-fluoranyl-3-(3-oxidanylidene-4-pentan-3-yl-piperazin-1-yl)carbonyl-phenyl]methyl]quinazoline-2,4-dione × 1 | X-RAY DIFFRACTION |
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；291 K；25% PEG-3350, 0.1 M Tris-HCl pH 8.3-8.5
|
Resolution 3.05 Å R-free 0.256 |
| 8HKN Mutated human ADP-ribosyltransferase 2 (PARP2) catalytic domain bound to approved drug Fluzoparib Deposited 2022-11-27 | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric（1） Consistent with protein count |
Chain B
230–581（352 aa）
|
Mutation：T349S,L351R,S353G,P354L | GOL GLYCEROL × 1 25I Fluzoparib × 1 | X-RAY DIFFRACTION |
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；291 K；25% PEG-3350, 0.1 M Tris-HCl pH 8.5
|
Resolution 2.50 Å R-free 0.261 |
| 8HKN Mutated human ADP-ribosyltransferase 2 (PARP2) catalytic domain bound to approved drug Fluzoparib Deposited 2022-11-27 | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric（1） Consistent with protein count |
Chain A
230–581（352 aa）
|
Mutation：T349S,L351R,S353G,P354L | GOL GLYCEROL × 1 25I Fluzoparib × 1 | X-RAY DIFFRACTION |
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；291 K；25% PEG-3350, 0.1 M Tris-HCl pH 8.5
|
Resolution 2.50 Å R-free 0.261 |
| 8HKO Mutated human ADP-ribosyltransferase 2 (PARP2) catalytic domain bound to Rucaparib Deposited 2022-11-27 | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric（1） Consistent with protein count |
Chain A
230–581（352 aa）
|
Mutation：T349S,L351R,S353G,P354L | GOL GLYCEROL × 5 RPB Rucaparib × 1 | X-RAY DIFFRACTION |
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；291 K；25% PEG-3350, 0.1 M Tris-HCl pH 8.5
|
Resolution 2.10 Å R-free 0.211 |
| 8HKO Mutated human ADP-ribosyltransferase 2 (PARP2) catalytic domain bound to Rucaparib Deposited 2022-11-27 | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric（1） Consistent with protein count |
Chain B
230–581（352 aa）
|
Mutation：T349S,L351R,S353G,P354L | GOL GLYCEROL × 1 RPB Rucaparib × 1 | X-RAY DIFFRACTION |
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；291 K；25% PEG-3350, 0.1 M Tris-HCl pH 8.5
|
Resolution 2.10 Å R-free 0.211 |
| 8HKS Mutated human ADP-ribosyltransferase 2 (PARP2) catalytic domain bound to Pamiparib(BGB-290) Deposited 2022-11-28 | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric（1） Consistent with protein count |
Chain A
230–581（352 aa）
|
Mutation：T349S,L351R,S353G,P354L | GOL GLYCEROL × 2 DS9 (2R)-14-fluoro-2-methyl-6,9,10,19-tetrazapentacyclo[14.2.1.02,6.08,18.012,17]nonadeca-1(18),8,12(17),13,15-pentaen-11-one × 1 | X-RAY DIFFRACTION |
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；291 K；25% PEG-3350, 0.1 M Tris-HCl pH 8.5
|
Resolution 2.80 Å R-free 0.238 |
| 8HKS Mutated human ADP-ribosyltransferase 2 (PARP2) catalytic domain bound to Pamiparib(BGB-290) Deposited 2022-11-28 | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric（1） Consistent with protein count |
Chain B
230–581（352 aa）
|
Mutation：T349S,L351R,S353G,P354L | GOL GLYCEROL × 5 DS9 (2R)-14-fluoro-2-methyl-6,9,10,19-tetrazapentacyclo[14.2.1.02,6.08,18.012,17]nonadeca-1(18),8,12(17),13,15-pentaen-11-one × 1 | X-RAY DIFFRACTION |
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；291 K；25% PEG-3350, 0.1 M Tris-HCl pH 8.5
|
Resolution 2.80 Å R-free 0.238 |
| 8HKS Mutated human ADP-ribosyltransferase 2 (PARP2) catalytic domain bound to Pamiparib(BGB-290) Deposited 2022-11-28 | Assembly 3 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric（1） Consistent with protein count |
Chain C
230–581（352 aa）
|
Mutation：T349S,L351R,S353G,P354L | GOL GLYCEROL × 2 DS9 (2R)-14-fluoro-2-methyl-6,9,10,19-tetrazapentacyclo[14.2.1.02,6.08,18.012,17]nonadeca-1(18),8,12(17),13,15-pentaen-11-one × 1 | X-RAY DIFFRACTION |
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；291 K；25% PEG-3350, 0.1 M Tris-HCl pH 8.5
|
Resolution 2.80 Å R-free 0.238 |
| 8HKS Mutated human ADP-ribosyltransferase 2 (PARP2) catalytic domain bound to Pamiparib(BGB-290) Deposited 2022-11-28 | Assembly 4 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric（1） Consistent with protein count |
Chain D
230–581（352 aa）
|
Mutation：T349S,L351R,S353G,P354L | GOL GLYCEROL × 3 DS9 (2R)-14-fluoro-2-methyl-6,9,10,19-tetrazapentacyclo[14.2.1.02,6.08,18.012,17]nonadeca-1(18),8,12(17),13,15-pentaen-11-one × 1 | X-RAY DIFFRACTION |
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；291 K；25% PEG-3350, 0.1 M Tris-HCl pH 8.5
|
Resolution 2.80 Å R-free 0.238 |
| 8HLJ Mutated human ADP-ribosyltransferase 2 (PARP2) catalytic domain bound to Olaparib (AZD2281) Deposited 2022-11-30 | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric（1） Consistent with protein count |
Chain A
230–581（352 aa）
|
Mutation：T349S,L351R,S353G,P354L | 09L 4-(3-{[4-(cyclopropylcarbonyl)piperazin-1-yl]carbonyl}-4-fluorobenzyl)phthalazin-1(2H)-one × 1 | X-RAY DIFFRACTION |
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；296.5 K；25% PEG-3350, 0.1 M Tris-HCl pH 8.5
|
Resolution 2.24 Å R-free 0.247 |
| 8HLJ Mutated human ADP-ribosyltransferase 2 (PARP2) catalytic domain bound to Olaparib (AZD2281) Deposited 2022-11-30 | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric（1） Consistent with protein count |
Chain B
230–581（352 aa）
|
Mutation：T349S,L351R,S353G,P354L | 09L 4-(3-{[4-(cyclopropylcarbonyl)piperazin-1-yl]carbonyl}-4-fluorobenzyl)phthalazin-1(2H)-one × 1 | X-RAY DIFFRACTION |
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；296.5 K；25% PEG-3350, 0.1 M Tris-HCl pH 8.5
|
Resolution 2.24 Å R-free 0.247 |
| 8HLQ Mutated human ADP-ribosyltransferase 2 (PARP2) catalytic domain bound to Niraparib (MK-4827) Deposited 2022-11-30 | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric（1） Consistent with protein count |
Chain A
230–581（352 aa）
|
Mutation：T349S,L351R,S353G,P354L | GOL GLYCEROL × 1 3JD 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide × 1 | X-RAY DIFFRACTION |
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；291 K；25% PEG-3350, 0.1 M Tris-HCl pH 8.5
|
Resolution 2.70 Å R-free 0.282 |
| 8HLQ Mutated human ADP-ribosyltransferase 2 (PARP2) catalytic domain bound to Niraparib (MK-4827) Deposited 2022-11-30 | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric（1） Consistent with protein count |
Chain B
230–581（352 aa）
|
Mutation：T349S,L351R,S353G,P354L | GOL GLYCEROL × 2 3JD 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide × 1 | X-RAY DIFFRACTION |
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；291 K；25% PEG-3350, 0.1 M Tris-HCl pH 8.5
|
Resolution 2.70 Å R-free 0.282 |
| 8JNY Mutated human ADP-ribosyltransferase 2 (PARP2) catalytic domain bound to a pyrazolopyrimidine carboxamide inhibitor Deposited 2023-06-06 | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric（1） Consistent with protein count |
Chain A
230–581（352 aa）
|
Mutation：T349S,L351R,S353G,P354L | ERV 6-methylpyrazolo[1,5-a]pyrimidine-3-carboxamide × 1 | X-RAY DIFFRACTION |
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.5；291 K；25% PEG-3350, 0.1 M Tris-HCl pH 8.5
|
Resolution 3.20 Å R-free 0.268 |
| 8JNY Mutated human ADP-ribosyltransferase 2 (PARP2) catalytic domain bound to a pyrazolopyrimidine carboxamide inhibitor Deposited 2023-06-06 | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric（1） Consistent with protein count |
Chain B
230–581（352 aa）
|
Mutation：T349S,L351R,S353G,P354L | ERV 6-methylpyrazolo[1,5-a]pyrimidine-3-carboxamide × 1 | X-RAY DIFFRACTION |
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.5；291 K；25% PEG-3350, 0.1 M Tris-HCl pH 8.5
|
Resolution 3.20 Å R-free 0.268 |
| 9IM8 Mutated ADP-ribosyltransferase 2 (PARP2) catalytic domain bound to a pyrimidine 2,4-diketone derivative inhibitor Deposited 2024-07-02 | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric（1） Consistent with protein count |
Chain A
230–581（352 aa）
|
Mutation：T349S,L351R,S353G,P354L | GOL GLYCEROL × 1 A1D9M 5-ethyl-1-[[3-[(3~{R})-4-ethyl-3-(2-hydroxyethyl)piperazin-1-yl]carbonyl-4-fluoranyl-phenyl]methyl]pyrimidine-2,4-dione × 1 | X-RAY DIFFRACTION |
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；291 K；25% PEG-3350, 0.1 M Tris-HCl pH 8.5
|
Resolution 2.10 Å R-free 0.241 |
| 9IM8 Mutated ADP-ribosyltransferase 2 (PARP2) catalytic domain bound to a pyrimidine 2,4-diketone derivative inhibitor Deposited 2024-07-02 | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric（1） Consistent with protein count |
Chain B
230–581（352 aa）
|
Mutation：T349S,L351R,S353G,P354L | A1D9M 5-ethyl-1-[[3-[(3~{R})-4-ethyl-3-(2-hydroxyethyl)piperazin-1-yl]carbonyl-4-fluoranyl-phenyl]methyl]pyrimidine-2,4-dione × 1 | X-RAY DIFFRACTION |
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；291 K；25% PEG-3350, 0.1 M Tris-HCl pH 8.5
|
Resolution 2.10 Å R-free 0.241 |
| 9ZQ9 Nucleosome with an SSB at SHL -2.8 in complex with the WGR domain of human PARP2, Class 1 Deposited 2025-12-18 | Assembly 1 Protein–DNA Heteromer；Protein × 11 PDB declaration: 14-meric（14） Consistent with all polymers |
Chain P
90–212（123 aa）
|
Not recorded | No recorded non-water small molecule | ELECTRON MICROSCOPY |
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.30 Å |
| 9ZQA Nucleosome with an SSB at SHL -2.8 in complex with the WGR domain of human PARP2, Class 2 Deposited 2025-12-18 | Assembly 1 Protein–DNA Heteromer；Protein × 11 PDB declaration: 14-meric（14） Consistent with all polymers |
Chain P
90–212（123 aa）
|
Not recorded | No recorded non-water small molecule | ELECTRON MICROSCOPY |
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.28 Å |
| 9ZQB Nucleosome with an SSB at SHL -2.8 in complex with human PARP2 and HPF1, Class 1 Deposited 2025-12-18 | Assembly 1 Protein–DNA Heteromer；Protein × 11 PDB declaration: 14-meric（14） Consistent with all polymers |
Chain P
90–583（494 aa）
|
Not recorded | No recorded non-water small molecule | ELECTRON MICROSCOPY |
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 2.10 Å |
| 9ZQC Nucleosome with an SSB at SHL -2.8 in complex with human PARP2 and HPF1, Class 2 Deposited 2025-12-18 | Assembly 1 Protein–DNA Heteromer；Protein × 11 PDB declaration: 14-meric（14） Consistent with all polymers |
Chain P
90–583（494 aa）
|
Not recorded | No recorded non-water small molecule | ELECTRON MICROSCOPY |
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 2.37 Å |